Comparison
Cagrilintide vs. Ipamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
170851-70-4
Molecular weight
4253.7 g/mol
711.86 g/mol
Half-life
168 h
2 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAib-His-D-2-Nal-D-Phe-Lys-NH2Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
3
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
1